Current Edition


Lawmakers blast pharma for ‘outrageous’ prices and ‘anticompetitive conduct’ in culmination of 3-year probe

For years, drugmakers have targeted “weaknesses” in the U.S. healthcare system to reap dividends on older meds, The House Oversight Committee said Friday. The “outrageous …

Continue Reading →

Novo Nordisk, Sanofi and Eli Lilly cut insulin prices and lose share in China’s latest cost squeeze

On the centennial of the discovery of insulin, China decided a round of price cuts on the diabetes therapy is due. As a result, foreign …

Continue Reading →

Viatris launched two versions of its interchangeable insulin biosimilar. Why?

It’s official: Biocon and Viatris have launched their historic interchangeable insulin biosimilar, Semglee. The drug, which references Sanofi’s blockbuster diabetes med Lantus, will roll out …

Continue Reading →

Significant blood sugar improvement with Xultophy® compared to insulin glargine U-100 when used as add-on to oral diabetes medications

Adults with type 2 diabetes treated with Xultophy® (insulin degludec and liraglutide injection) also experienced no change in body weight, lower rates of hypoglycaemia and …

Continue Reading →
BRIGHT study

Sanofi’s Toujeo® met main objective in head-to-head study versus insulin degludec

Sanofi’s Toujeo® met the primary study objective in the first large head-to-head clinical trial1, called BRIGHT study, comparing Toujeo with insulin degludec. Sanofi plans to …

Continue Reading →
clinical trial

Xultophy® reported a better option than basal-bolus insulin therapy to manage type 2 diabetes by participants in the DUAL VII clinical trial

Once-daily Xultophy® (insulin degludec/liraglutide) was a better option to manage diabetes compared to multiple daily injections of insulin (basal-bolus regimen). This was reported by people …

Continue Reading →

Imcyse continues patient enrolment in its Phase 1b trial in type 1 diabetes

Imcyse, a biotechnology company developing active specific therapies for the treatment of severe chronic diseases, today announces that it began recruiting patients into its multicenter …

Continue Reading →